IRLAB: Invitation to the interim report for Q1 2026 presentation and webcast

Gothenburg, Sweden, April 30, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company will hold a presentation in conjunction with the publication of the interim report for the period January – March 2026. The interim report will be published on Wednesday, May 6, 2026, at 07:00 CEST.

IRLAB publishes the Annual Report for 2025

Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026